Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in a NetworkNewsWire editorial that sheds light on the company’s precision genetic medicine platform. This platform is designed to target primary and metastatic cancer tumors through the use of engineered viruses, marking a significant advancement in the field of oncology. With projections indicating that global cancer diagnoses could reach 35 million annually by 2050, the need for innovative treatments has never been more critical. Calidi’s approach focuses on delivering potent genetic therapies directly to cancer sites, offering a novel solution that could potentially disrupt current cancer treatment methodologies.
The company’s technology leverages engineered viruses to arm the immune system against cancer, utilizing allogeneic stem cells capable of carrying oncolytic viruses. This method aims to enhance the efficacy of treatments while improving patient safety, addressing some of the most pressing challenges in cancer therapy today. Calidi Biotherapeutics is at the forefront of developing treatments for high-grade gliomas and solid tumors, with its clinical stage off-the-shelf, universal cell-based delivery platforms. Additionally, its preclinical enveloped virotherapies are designed to target disseminated solid tumors, offering a dual approach that could treat or even prevent metastatic disease.
For more information on Calidi Biotherapeutics and its groundbreaking work in genetic medicine, visit https://ibn.fm/GZS7L. The company’s efforts represent a beacon of hope in the ongoing battle against cancer, providing a glimpse into the future of oncology treatment where precision and innovation lead to better patient outcomes.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Calidi Biotherapeutics Inc. Featured for Breakthrough Genetic Medicine Platform in Cancer Treatment.
